Erika Check, Washington
The troubled field of gene therapy was dealt a fresh blow this week, after a study suggested that modified viruses used in some trials might cause health problems.
The study, led by geneticist Mark Kay at Stanford University, California, examined a modified virus used in gene-therapy trials to treat haemophilia and cystic fibrosis. It revealed that the virus has the potential to cause the same problems that led to cancer in an unrelated gene-therapy trial last year.
In gene therapy, doctors use a gutted virus as a 'vector' to transfer corrective genes into a patient's cells. But if the vector stitches itself into a cell's genes, it can cause the cell to mutate and become cancerous. This was demonstrated last year, when two children who had gene therapy for severe combined immunodeficiency disease (SCID) developed leukaemia (see Nature 419, 545-546; 2002) .
Scientists are still trying to establish exactly why the SCID patients developed cancer, and will discuss the trial at this week's meeting of the American Society of Gene Therapy in Washington DC. But most agree that gene therapy was the cause.
Kay's study focused on a vector made from an adeno-associated virus -an organism that does not cause disease in people, but which can be engineered to infect human cells. In a paper published online on 1 June (H. Nakai et al. Nature Genet. doi:10.1038 2003) Protests win reprieve for renowned medical lab But researchers caution that the vector used in the SCID trials, which was based on a retrovirus, is very different from the adeno-associated vector. For instance, retroviruses must insert themselves into human DNA to work, but adeno-associated viral vectors integrate themselves into the genome much less often.
"Adeno-associated vectors clearly have a better safety profile than retroviral vectors," says David Russell, a geneticist at the University of Washington in Seattle. "But we really can't say yet that adenoassociated vectors won't cause cancer." Kay's team, which is running a genetherapy trial for haemophilia, tracked the adeno-associated viral vectors in mice. They extracted liver cells whose DNA contained the vector and then sequenced the DNA around the vector. They then analysed the sequences to see whether they matched a known gene. The team found that 72% of the time, the vector had interrupted a gene. Had it inserted itself randomly, the vector would have interrupted a gene no more than 40% of the time.
Last August, Frederic Bushman and his colleagues at the Salk Institute for Biological Sciences in La Jolla, California, suggested that retroviruses also insert themselves into genes more often than into other regions of DNA (A. R. Schroder et al. Cell 110, 521-529; 2002) .
Such results are leading researchers to seek better ways to target vectors to specific regions of DNA, and to develop vectors that don't integrate into DNA at all. But in the meantime, Kay says that he has taken numerous precautions to protect the 14 haemophiliacs he has treated. "I don't think we need to modify anything at this point," Kay says. "But this is a risk we'll have to address before the vector is in widespread use." 
Jonathan Knight, San Francisco
An ambitious effort to hammer out an agreement between proponents and critics of agricultural biotechnology in the United States has ended in failure.
Two years of talks, convened in 2001 by the Washington-based Pew Initiative on Food and Biotechnology, reached an impasse late last month over the question of whether to ask Congress for legislation to strengthen regulations for transgenic food.
The 18-member panel was set up to produce detailed guidelines for safety standards for genetically modified products. But the ground rules for the panel required unanimous agreement on all issues under consideration before any conclusions would be made public. "It was an extremely ambitious effort," says Margaret Mellon, a panel member and director of the food and environment programme at the Union of Concerned Scientists in Washington DC. "We were going for the brass ring, and we didn't get it."
One issue that was contentious from the start was whether new laws are needed to guarantee the safety of transgenic food. The biotechnology industry opposes the involvement of Congress in favour of minor administrative changes to the current approval process. But consumer and environmental groups say that the present voluntary system is inadequate and needs a legislative fix. Panel members confirm that disagreement on this point was critical to the failure of the process.
Some observers suggest that the recent trade complaint filed at the World Trade Organization (WTO) by the United States against the European Union (see Nature 423, 369; 2003) might have contributed to the problem by entrenching industry's position. "The case is being made on the grounds that the current regulatory process is safe," says Robert Paarlberg, an expert in international agricultural policy at Wellesley College near Boston. "The industry doesn't want any suggestion that it isn't." Panel member Richard Caplan, an environmental advocate with the US Public Interest Research Group in Washington DC, says that although the WTO suit was not discussed in the sessions, it could have been a factor. But Mike Rodemeyer, executive director of the Pew Initiative, says that he strongly doubts whether it made any difference. Roberts says that individual ratings would not be published, but sceptics doubt whether the scores could be kept from researchers. "How will that information be denied them?" asks Keith Peters, an immunologist at the University of Cambridge and president of the Academy of Medical Sciences. Roberts concedes that individual rankings should not be used if they cannot be kept secret.
Roberts' review, which was commissioned by the UK higher-education funding councils, also suggests separating out the least researchintensive universities and subjecting them to a shorter review process. That idea has drawn fire from some of the smaller universities. "It is divisive," says Mike Saks, pro-vicechancellor for research at the University of Lincoln. The university received just £250,000 this year from the funding councils, but Saks says it has begun a major drive to improve its research and doesn't want to be put in a second class of institutions.
The funding councils, which distribute £1.1 billion (US$1.8 billion) to universities each year, largely on the basis of the RAE, are accepting comments on the new plan until September. They will then decide how to do the next assessment, most likely in 2007. 
